Abstract-Myocardial infarctions are the leading cause of death for both men and women in the United States. Current treatment techniques return blood flow to the infarcted tissue, but do not replace the dead cells with contractile cells. Research pertaining to human mesenchymal stem cells has shown promise in the ability to regrow and proliferate cardiac myocytes. Biological microthreads have been shown to efficiently deliver cells to the heart. However, a minimally invasive device to deliver cell seeded biological threads is needed to move the technology into the clinic. Therefore, we developed a cardiac catheterization device to deliver microthreads seeded with human mesenchymal stem cells to the left ventricular wall.
I. INTRODUCTION
Myocardial infarction (MI) is the leading cause of death for both men and women in the United States. Each year, an MI affects approximately 1.7 million people with 460,000 cases being fatal [1] . Myocardial infarction occurs when the cells of the heart muscle begin to die from inadequate blood supply. Current treatments return blood flow to ischemic tissue, but the heart muscle that has died remains inactive and reduces the overall functionality of the heart. As the heart lacks the ability to regenerate contractile cells, exogenous cells are needed to restore function to the heart.
Human mesenchymal stem cells (HMSCs) show great potential for research in the realm of cardiac regeneration. Recent research shows evidence that HMSCs can produce the cardiac specific protein actinin, which suggests the HMSCs ability to differentiate into cardiac myocytes and/or induce existing myocytes to proliferate [2] . Biological microthreads, comprised of collagen and/or fibrin, have been shown to improve efficiency of cell retention compared to other commonly used techniques [3] . It is the goal of this project to develop a catheter system to allow for the minimally invasive delivery of cell-seeded microthreads to the left ventricular wall, which may aid in repairing the damaged heart tissue caused by an MI.
II. METHODS AND MATERIALS
We determined that a catheter-based system would efficiently deliver HMSCs to the left ventricular wall. This design aimed at correcting multiple problems existing with suturing microthreads into the heart wall. Currently, delivery of cell-seeded microthreads relies on an epicardial approach to suture the microthreads into the heart wall. This approach can create shear stress that removes cells from the microthread at the point of entry on the heart wall. This results in dramatically lower engraftment rates. Therefore, reduction of shear stress on cells seeded on a microthread was a function considered in this design. A minimally invasive approach to delivering biological microthreads is needed to further the development of this treatment in the clinical setting.
A successful design would be minimally invasive, able to deliver the catheter and cell-seeded microthreads to the left ventricular wall, be visible with current technology, maintain cell viability and be easy to use. While navigating through the arterial system, starting at the femoral, the catheter cannot damage the vessels. To visualize the catheter device Solidworks was used to create a CAD model. Once the design worked in theory, with Solidworks, the individual components were purchased or created. The handle at the proximal end as well as several components of the distal end were created using 3D print rapid prototyping. Lumen and guidewires were purchased from McMaster-Carr. The monetary budget did not allow for purchasing custom extruded lumen. However, this provides a proof of concept working prototype.
The catheter must be inert and non-thrombogenic in order to not disturb ongoing bodily functions. Plastics were researched for their ability to provide the desired biocompatibility as well as manufacturability. In order to properly test the concepts put forth by the design, the individual components were tested to determine feasibility. To provide an environment where the HMSCs were capable of surviving using an expandedpolytetrafluoroethylene (ePTFE) membrane was explored. The burst pressure of the ePTFE membrane was determined by a controlled lowering of a needle into the material attached to the force gauge.
III. RESULTS
The final design incorporates a dual needle enclosed within a capsule. An inner core is capable of holding 1.4cm of microthread with a diameter of 600μm. The inner core is placed within a 16gauge needle and the entire assembly is enclosed within a capsule with an outer diameter of 3mm. This capsule allows for multiple procedures to occur in rapid succession. The biological microthreads are placed within the capsule on the inner core making loading the device more user friendly. The entire assembly is attached to a 9Fr catheter. Materials used are of conventional medical grade. The needle is made of 316L stainless steel. The capsule, inner core and accessory attaching mechanisms are made of medical grade acrylonitrile butadiene styrene (ABS). This design is compatible with current technology for visualizing the catheter within the body, for example fluoroscopy. The catheter was intended to be used starting at the femoral artery in the groin. It would then be advanced to the aortic arch where the left ventricle could be accessed. and proximal ends of the catheter work in order to deliver the microthread to the desired location within the left ventricle. Figure 1a shows the starting position of the catheter. The double slide actuator on the handle is set to the back of the handle and the delivery mechanism at the distal end is enclosed within the capsule. Figure 1b shows the advancement of the entire needle apparatus. At this point the entire mechanism is within infarcted heart tissue. Figure 1c shows the primary slide switch pulled back revealing the inner core and microthreads to the heart tissue. Figure 1d depicts the entire assembly retracted back into the capsule and ready for removal from the left ventricle. Only the biological microthread is left behind within the heart wall.
IV. DISCUSSION AND CONCLUSION The primary goal of this project was to create a minimally invasive device that was capable of delivering stem-cell seeded biological microthreads to the left ventricular wall. In order to accomplish this, we designed a novel two-needle delivery which allows the HMSCs to be shielded as they enter the heart tissue. Once the entire mechanism is within the wall of the ventricle the outer needle can safely be retracted without any shear stress on the microthreads. The capsular approach was also important in providing doctors a way to place more than one thread within the heart wall. Once the femoral artery is tapped the catheter can be removed and a new capsule with more microthreads can be placed at the distal end. The procedure can be repeated as necessary with a single incision at the groin, not open-heart surgery. Continuing this work would involve scaling the device to be used in a 7Fr catheter approximately 1mm smaller than the 9Fr called for in the current design. Budget considerations limited the group's manufacturing capabilities. A 9Fr catheter is an acceptable size, but a 7Fr would allow for additional blood flow during the procedure.
